Last Price$143.1(8.0%)
Market Cap$18.5B
LTM Total Liabilities
$712.4M
YoY Growth
+7.6%
3Y CAGR
+8.9%
5Y CAGR
+19.2%
Stock quality & Intrinsic value
6/10
50.4% overvalued
Natera, Inc. Total Liabilities
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Liabilities | $138.9M | $231.2M | $295.0M | $80.5M | $104.2M | $189.1M | $236.0M | $303.9M | $445.9M | $583.2M | $688.7M | $676.4M |
Overvalued or undervalued?
Check the intrinsic value for NTRA
and see if it's the right time to invest.
Natera, Inc. (NTRA) Total Liabilities comparison analysis
General
LTM Total Liabilities
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Natera, Inc.NTRA
$712.4M
7.6%
8.9%
19.2%
Median Peer Set
$7,631.0M
(5.9%)
0.3%
4.5%
Thermo Fisher Scientific Inc.TMO
$47.8B
(7.9%)
(4.1%)
10.7%
Danaher CorporationDHR
$28.0B
(9.7%)
(9.7%)
(2.5%)
IQVIA Holdings Inc.IQV
$20.8B
1.3%
3.8%
4.2%
Laboratory Corporation of America HoldingsLH
$10.3B
16.7%
0.7%
(0.3%)
Quest Diagnostics IncorporatedDGX
$9,375.0M
23.3%
10.0%
5.8%
Agilent Technologies, Inc.A
$5,887.0M
23.7%
4.4%
4.8%
Illumina, Inc.ILMN
$3,591.0M
(17.8%)
(7.1%)
5.8%
Mettler-Toledo International Inc.MTD
$3,366.9M
(4.0%)
2.2%
7.3%
Waters CorporationWAT
$2,725.3M
(21.6%)
(0.0%)
(0.3%)
IDEXX Laboratories, Inc.IDXX
$630.2M
(64.5%)
(28.8%)
(17.6%)
NTRA key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 14.3 0.0% | 55.2 287.2% | 159.3 188.7% | 190.4 19.5% | 217.1 14.0% | 210.9 (2.8%) | 257.7 22.1% | 302.3 17.3% | 391.0 29.3% | 625.5 60.0% | 820.2 31.1% | 1,082.6 32.0% |
| Cost of Goods Sold (COGS) | 11.2 | 37.3 | 78.4 | 112.8 | 135.6 | 139.6 | 166.1 | 175.5 | 203.6 | 318.4 | 456.3 | 589.8 |
% margin | 3.1 21.7% | 17.9 32.4% | 80.9 50.8% | 77.5 40.7% | 81.5 37.5% | 71.3 33.8% | 91.6 35.6% | 126.9 42.0% | 187.4 47.9% | 307.1 49.1% | 364.0 44.4% | 492.7 45.5% |
| Operating Expenses | 22.3 | 43.2 | 80.2 | 137.3 | 178.0 | 205.4 | 206.2 | 257.5 | 403.7 | 775.2 | 905.0 | 939.0 |
| Research & Development Expenses (R&D) | 7.0 | 11.6 | 17.3 | 27.7 | 41.9 | 50.1 | 51.4 | 51.4 | 100.0 | 264.2 | 316.4 | 320.7 |
| Selling, General & Administrative Expenses (SG&A) | 15.3 | 31.6 | 62.9 | 109.6 | 136.1 | 155.3 | 154.9 | 206.2 | 303.6 | 511.0 | 588.6 | 618.3 |
% margin | (19.2) (134.8%) | (25.3) (45.8%) | 0.7 0.4% | (59.8) (31.4%) | (96.5) (44.4%) | (134.0) (63.5%) | (114.6) (44.5%) | (130.7) (43.2%) | (216.3) (55.3%) | (468.2) (74.8%) | (541.0) (66.0%) | (446.2) (41.2%) |
| Interest Income | 57.0 | 0.0 | 0.1 | 1.0 | 1.4 | 2.4 | 0.0 | 4.2 | 7.6 | 5.4 | 3.5 | 24.4 |
| Interest Expense | 0.0 | 11.9 | 4.2 | 3.5 | 0.5 | 4.2 | 10.5 | 10.7 | 15.1 | 8.3 | 9.3 | 12.6 |
| Pre-tax Income | (76.2) | (37.1) | (5.2) | (70.3) | (95.6) | (135.9) | (127.8) | (122.8) | (229.6) | (471.1) | (546.8) | (434.5) |
% effective tax rate | 0.0 0.0% | 12.0 (32.4%) | 2.5 (48.6%) | (9.9) 14.1% | 0.1 (0.1%) | 0.5 (0.3%) | 0.3 (0.3%) | 2.0 (1.6%) | 0.1 (0.0%) | 0.6 (0.1%) | 1.0 (0.2%) | 0.3 (0.1%) |
% margin | (76.2) (534.5%) | (37.1) (67.3%) | (5.2) (3.2%) | (70.3) (36.9%) | (95.8) (44.1%) | (136.3) (64.6%) | (128.2) (49.7%) | (124.8) (41.3%) | (229.7) (58.8%) | (471.7) (75.4%) | (547.8) (66.8%) | (434.8) (40.2%) |
| EPS | (24.37) | (1.01) | (0.14) | (2.68) | (1.86) | (2.56) | (2.22) | (1.79) | (2.84) | (5.21) | (5.57) | (3.78) |
| Diluted EPS | (24.37) | (1.01) | (0.14) | (2.68) | (1.86) | (2.54) | (2.22) | (1.79) | (2.84) | (5.21) | (5.57) | (3.78) |
% margin | (18.5) (129.8%) | (22.7) (41.2%) | 4.2 2.6% | (61.2) (32.2%) | (93.4) (43.0%) | (125.8) (59.6%) | (107.1) (41.6%) | (104.4) (34.5%) | (206.0) (52.7%) | (451.5) (72.2%) | (520.8) (63.5%) | (383.3) (35.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Natera, Inc.'s Total Liabilities?
As of today, Natera, Inc.'s last 12-month Total Liabilities is $712.4M, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Natera, Inc.'s Total Liabilities growth rate?
Over the last year, Natera, Inc.'s Total Liabilities growth was 7.6%. The average annual Total Liabilities growth rates for Natera, Inc. have been 11.0% over the past three years, 19.2% over the past five years.
3) Is Natera, Inc.'s Total Liabilities growth rate Good?
Over the last year, Natera, Inc.'s Total Liabilities growth was 7.6%, which is higher than industry growth of 0.1%. It indicates that Natera, Inc.'s Total Liabilities growth is Good.